(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 14.95% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.85%.
Grail's revenue in 2025 is $134,285,000.On average, 6 Wall Street analysts forecast GRAL's revenue for 2025 to be $5,293,619,283, with the lowest GRAL revenue forecast at $4,995,143,507, and the highest GRAL revenue forecast at $5,499,812,693. On average, 6 Wall Street analysts forecast GRAL's revenue for 2026 to be $6,371,448,473, with the lowest GRAL revenue forecast at $5,652,294,883, and the highest GRAL revenue forecast at $7,267,236,278.
In 2027, GRAL is forecast to generate $7,522,454,695 in revenue, with the lowest revenue forecast at $6,040,890,156 and the highest revenue forecast at $8,648,948,414.